Literature DB >> 12418465

Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? For.

Thomas M Behr1.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12418465     DOI： 10.1007/s00259-002-0928-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  30 in total

1.  Critical Lym-1 binding residues on polymorphic HLA-DR molecules.

Authors:  L M Rose; C T Deng; S L Scott; C Y Xiong; K R Lamborn; P H Gumerlock; G L DeNardo; C F Meares
Journal:  Mol Immunol       Date:  1999-08       Impact factor: 4.407

2.  Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.

Authors:  R M Sharkey; T M Behr; M J Mattes; R Stein; G L Griffiths; L B Shih; H J Hansen; R D Blumenthal; R M Dunn; M E Juweid; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1997-05       Impact factor: 6.968

Review 3.  Targeted therapy of cancer with radiolabeled antibodies.

Authors:  David M Goldenberg
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

Review 4.  Radiolabeled antibody therapy of B-cell lymphomas.

Authors:  O W Press
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

5.  A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.

Authors:  O W Press; J F Eary; T Gooley; A K Gopal; S Liu; J G Rajendran; D G Maloney; S Petersdorf; S A Bush; L D Durack; P J Martin; D R Fisher; B Wood; J W Borrow; B Porter; J P Smith; D C Matthews; F R Appelbaum; I D Bernstein
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

6.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

Review 7.  Hodgkin's disease and transplantation: a room with a (nontransplanter's) view.

Authors:  N A Marshall; V T DeVita
Journal:  Semin Oncol       Date:  1999-02       Impact factor: 4.929

8.  Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.

Authors:  M S Kaminski; J Estes; K R Zasadny; I R Francis; C W Ross; M Tuck; D Regan; S Fisher; J Gutierrez; S Kroll; R Stagg; G Tidmarsh; R L Wahl
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

9.  High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.

Authors:  Thomas M Behr; Frank Griesinger; Joachim Riggert; Stefan Gratz; Martin Béhé; Cornelia C Kaufmann; Bernhard Wörmann; Gerhard Brittinger; Wolfgang Becker
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

10.  Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.

Authors:  T M Behr; R M Sharkey; M E Juweid; R M Dunn; Z Ying; C H Zhang; J A Siegel; D M Goldenberg
Journal:  J Nucl Med       Date:  1997-03       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.